• Building global commercial strategy for a novel molecule in separate Phase 2 clinical trials for Essential Tremor and Parkinson’s Disease Tremor• Leading a cross-functional team accountable for gaining in-depth market insights, strengthening Target Product Profile differentiation and developing early global positioning and branding.• Representing global commercial within the molecule Late Stage Development team

Led organizational strategy with a focus on developing and implementing growth strategies that expand innovative programs and diversify funding • Young adults with a diagnosis of a severe mental illness (schizophrenia, bipolar disorder, MDD)• Individuals with a substance use disorder (addiction)Partnered with a Clinic Director to design and launch an entrepreneurial new service focused on helping parents manage "screen time" with their children, including behavioral health challenges with social media• Educational events and workshops in partnership with local schools and parent organizations• Built and launched an online consultation service with integrated scheduling and payment

•Opportunity assessments and commercial strategies from discovery into Phase 3 with 27 clinical phase go/no-go milestone decisions across nine diseases/conditions from small orphan diseases (progressive supranuclear palsy, spinal cord injury) to large indications (Alzheimer's Disease, MDD, addictions) since 2008•Led a Disease Opportunity Profile project for neurorestoration in multiple sclerosis with a cross-functional team including discovery, clinical, regulatory, market access and BDL&A. Gained senior leadership endorsement of Aspirational Product Concepts with R&D strategies to achieve them ­ - Cross-functional team included discovery, clinical, regulatory, market research, market access and BDL&A­ - Supported advancement of ABT-555 (anti-RGMa) into clinical development, including TPP and evidence generationLed a Parkinson’s Disease Franchise Expansion project, which supported a broadening of AbbVie’s Neuroscience strategy, including advancement of combination drug/device product ABBV-951 into clinical development ­- Collaboration across discovery, clinical, medical affairs, regulatory, HEOR, Duodopa/Duopa and BDL&A stakeholders­- Neuroscience leadership complimented the team and incorporated the project into 2015 long-range plan strategy

•Led commercial strategy for Alzheimer's Disease, addictions, mood disorders and schizophrenia•Led a Disease Opportunity Profile project for schizophrenia cognitive impairment and negative symptoms and gained senior leadership endorsement of Aspirational Product Concepts with R&D strategies to achieve them­- Supported advancement of ABT-126 (α7 NNR) into clinical development•Managed advisory board meetings, market research, competitive assessments and forecasts to inform product milestone decisions, portfolio reviews and clinical trial designs

•Led opportunity assessments for smoking cessation and psychoses with cross-functional teams•Refined TPPs and completed financial valuations for smoking cessation within the first seven weeks in the role

•Led commercial input from early discovery to Phase 3 for NMEs targeting psychoses, mood disorders and addictions ­- Opportunity assessment for a novel mechanism targeting alcohol use disorders and gained support to advance into Phase 2a­- Gained high-level input from global areas to inform Phase 2 design, resulting in a change to comparator assumptions for EU •Collaborated with discovery research, medical, health outcomes, regulatory, market research and finance functions

•Led the U.S. marketing planning process for a $3.2B anti-psychotic indicated for schizophrenia and bipolar disorder•Ad agency liaison for development, testing and launch of a new creative campaign to reposition the brand •Facilitated strategic alignment of marketing programs across 11 sub-teams and promoted the use of customer segmentation and marketing analytics including brand equity, marketing effectiveness and channel mix modeling•Proposed, designed and implemented mental health advocacy partnerships to recognize mental health professionals ­ - Collaborated with MHA and NAMI to design and sponsor local mental health professional recognition programs­ - Partnered with State Government Affairs to implement six pilot programs in 2005, expanded to 24 in 2006

•Coordinated eight late-stage licensing deals across cardiovascular, critical care, diabetes, oncology and neuroscience including the $380MM Byetta partnership with Amylin Pharmaceuticals•Facilitated deal process including deal strategy, valuations, term sheets, negotiations and final contracting spanning senior management, strategy, R&D, marketing, finance, legal, regulatory, manufacturing and the Japanese Affiliate

•Managed 27 health care accounts ($2mm annual sales); grew revenue by 11.4% in 2000 versus division decline of 5.6%•Client business development spanning strategy, market research, relationship marketing operations and financial planning.­- Helped a MN health system complete six service line business plans and a physician capacity study­- Completed market-based financial planning pilot projects to guide expansion and capital investment

•Managed a team of six Service Account Managers and co-led hiring, training and account management processes.

•Trained and supported 30 clients on computer software and online applications (market assessment, demand forecasting, consumer segmentation, psychographic insights, target marketing and clinical benchmarking)

•Led strategic planning consulting projects for hospital clients and co-designed the Service Account Manager role